NCT01642277View on ClinicalTrials.gov

Bacterial Genomic Sequencing in Overactive Bladder

PHASE2CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions
Overactive Bladder
Interventions
DRUG

Solifenacin

5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks

Trial Locations (1)

60153

Loyola University Chicago Health Sciences Division, Maywood

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Loyola University

OTHER

NCT01642277 - Bacterial Genomic Sequencing in Overactive Bladder | Biotech Hunter | Biotech Hunter